Cortical Dysplasia: Causes, Risk Factors, and Understanding the Condition

Cortical dysplasia (CD) is a congenital malformation of cortical development characterized by abnormal neuronal organization, lamination, and/or cytology. It is a leading cause of drug-resistant epilepsy.

Etiology: Multifactorial

  • Genetic: Somatic mutations in mTOR pathway genes (MTOR, DEPDC5, NPRL2/3, AKT3, PIK3CA, TSC1/2) – focal cortical dysplasia (FCD) types IIa/IIb. Germline mutations in tubulinopathies (TUBA1A, TUBB2B), FLNA, DCX (lissencephaly spectrum).
  • Prenatal insults: Intrauterine infection (CMV, Zika, toxoplasmosis), ischemia/stroke, teratogens (alcohol, valproate), metabolic disorders.
  • Developmental disruption: Abnormal neuronal proliferation, migration, differentiation, or apoptosis (weeks 8–24 gestation critical).
  • Vascular: Disrupted cortical angiogenesis → ischemic/hypoxic injury.

Classification (ILAE 2022)

  • Type I (architectural): Abnormal lamination (Ia) or columnar organization (Ib) – mild cytology.
  • Type II (cytological + architectural): Dysmorphic neurons (IIa) + balloon cells (IIb) – "Taylor-type balloon cells."
  • Type III: CD + another principal lesion (hippocampal sclerosis, tumor, vascular malformation, early injury).

Clinical Presentation

  • Epilepsy (often focal, drug-resistant) – typical onset childhood/adolescence.
  • Focal cognitive deficits (language, memory, executive) depending on location.
  • Motor deficits if motor cortex involved.

Diagnosis

  • MRI: High-resolution 3T epilepsy protocol – FCD signs: cortical thickening, blurred gray-white junction, transmantle sign (Type IIb), hyperintensity on FLAIR.
  • EEG: Focal epileptiform discharges.
  • FDG-PET: Hypometabolism in dysplastic zone.
  • Genetic testing: Panel for mTORopathies, tubulinopathies if bilateral/familial.

Treatment

  • Antiseizure medications: Often polytherapy; limited efficacy in FCD II.
  • Epilepsy surgery: Resection of dysplastic tissue – best chance for seizure freedom (60–80% for FCD II).
  • Neuromodulation: VNS, RNS if not surgical candidate.
  • mTOR inhibitors (everolimus/sirolimus): Emerging for mTOR-related CD (TSC, FCD IIb).

Multidisciplinary epilepsy center evaluation is essential for drug-resistant cases.

Genetic Disorders - Related Articles